SYK - Stryker Corporation
A medical technology company specializing in orthopedic implants, surgical equipment, and neurotechnology — a steady compounder in the healthcare devices space.
Finlify Score
31.4 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$348.04
-1.20%
52W Range
$281.00 - $404.14
Market Cap
$120.7B
-1.2%Compared to previous day
2026 Q1 Revenue
$6.0B
-16.1%Changes from last reporting quarter
2026 Q1 EPS
$1.00
Diluted shares
Analyst Rating
35 analysts in latest ratings feed
RSI
58.2
40-70 moderate
2Y Range Position
54%
-14.3% from high / +23.9% from low
Beta
0.77
Relative to market benchmark
MACD
2.91
MACD line 7.07 / signal line 4.16
Fundamental Trend
Growth 14.2Financial Health
Quality 61.1Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID31.4 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $6.0B-16.1% | $7.2B+18.4% | $6.1B+0.6% | $6.0B+2.7% |
| Gross Profit | $3.8B-17.7% | $4.6B+20.1% | $3.9B+0.3% | $3.8B+2.6% |
| Operating Income | $936M-48.1% | $1.8B+58.9% | $1.1B+2.0% | $1.1B+33.0% |
| Net Income | $745M-12.2% | $849M-1.2% | $859M-2.8% | $884M+35.2% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
The Finlify signal for SYK is AVOID, with a Finlify Score of 28.6 out of 100, which appears to be primarily influenced by weaker scores in Relative Strength and Fundamental Trend.
Technical
The asset's Relative Strength score of 12.8/100 suggests underperformance compared to its peers. While the 20-day return shows a modest gain of 1.7%, the 60-day return indicates a decline of 3.1%, and the stock is currently 17.7% below its 52-week high. The Accumulation/Volume score of 41.0/100 suggests somewhat limited buying interest.
Fundamentals
The Fundamental Trend score of 14.2/100 appears to be a significant drag on the overall Finlify score, suggesting potential concerns regarding recent fundamental performance. Despite this, the Financial Quality score of 61.1/100 indicates a generally sound financial position. The asset trades at a P/E ratio of 38.9x and a P/S ratio of 5.0x, which may suggest a premium valuation, while offering a dividend yield of 1.10%.
Macro Context
The current macro environment, characterized by an elevated 10Y Treasury Yield of 4.7% and a positive yield spread of 0.4%, may present a challenging backdrop for growth-oriented sectors like healthcare, potentially influencing investor sentiment for SYK.
Key Risks
- The low Relative Strength score of 12.8/100 and a negative 60-day return of -3.1% suggest recent underperformance.
- A very low Fundamental Trend score of 14.2/100 may indicate deteriorating business prospects or challenges in recent financial periods.
- The asset's premium valuation metrics (P/E of 38.9x, P/S of 5.0x) could increase its sensitivity to future earnings in a higher interest rate environment.